Project Grant R21AI185169
Award Date 8/20/25
Completion Date 7/31/27
Dollars Obligated $302K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $690,538 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Washington for the project "EXPANDING ACCESS AND IMPACT OF TUBERCULOSIS PREVENTIVE THERAPY: COMMUNITY-FRIENDLY DELIVERY AND MONITORING OF TPT TO IMPROVE UPTAKE AND REDUCE TB TRANSMISSION." The project aims to explore new, person-friendly models of tuberculosis preventive therapy (TPT) delivery to...
- This federal Project Grant award, totaling $404,108, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to identify the key genetic and signaling pathways that enable Mycobacterium tuberculosis (MTB) to form antibiotic persister cells, which can survive prolonged exposure to lethal antibiotics. The research aims to apply genetic and proteomic approaches to...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $750,000 Project Grant to The University of Southern Mississippi to research the role of extracellular polyphosphate in Mycobacterium tuberculosis antibiotic tolerance. The 4-year grant, which begins on Sep 20, 2025 and runs through Aug 31, 2029, aims to investigate the metabolic pathways in M. tuberculosis that regulate extracellular...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $298,829 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Tarn Biosciences, Inc. to develop novel nitroreductase-activated inhibitor compounds as treatments for tuberculosis (TB) and nontuberculous mycobacterial (NTM) infections. The funding, awarded on August 21, 2025, supports the discovery and preclinical development of a lead candidate compound, HC2210, which has shown...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $774,881 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to The Johns Hopkins University on February 24, 2025. The grant will support research to investigate the use of pro-apoptotic drugs, such as navitoclax, as host-directed therapies for treating pulmonary tuberculosis (TB). The research aims to evaluate how these drugs impact lung immune response, tissue...
- The University of Washington received a $188,760 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The grant supports research to investigate the role of the lung inflammatory environment and cellular milieu in controlling Mycobacterium tuberculosis (MTB) infection and preventing tuberculosis (TB) disease. Specifically, the research will test the hypothesis that interferon gamma-activated...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,248,740 Project Grant through the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to Michigan State University on July 7, 2025. The grant supports the development of a new series of nitrofuran compounds that are potent inhibitors against Mycobacterium tuberculosis (MTB) and Mycobacterium abscessus (MAB), the bacteria that cause tuberculosis and non-tuberculous mycobacterial infections,...
- The University of Washington received a $147,486 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to investigate the role of gamma delta (GD) T cells in controlling Mycobacterium tuberculosis (MTB) infection, which causes tuberculosis (TB). Key objectives include: Evaluating the molecular mechanisms underlying VD1 T cell recognition of mycobacterial...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $429,546 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to National Jewish Health in Colorado. The grant will fund research to evaluate the efficacy of tuberculosis (TB) treatment regimens by analyzing the transcriptomic patterns of Mycobacterium tuberculosis injury and adaptation during drug treatment. The research aims to develop more reliable preclinical measures of TB treatment...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,922,220 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University. The grant supports research to advance apoptosis-inducing agents as host-directed therapy for tuberculosis (TB). The research aims to boost host immune responses via the intrinsic apoptosis pathway to reduce Mycobacterium tuberculosis (MTB) growth and enhance the bactericidal activity of...